Management of Insulin Levels in PCOS

Screening and Assessment

The American Academy of Family Physicians recommends screening every PCOS patient for metabolic dysfunction regardless of body weight, as insulin resistance occurs independent of BMI and affects both lean and overweight women 4
The American College of Physicians suggests obtaining fasting glucose followed by 2-hour glucose level after 75-gram oral glucose load to detect type 2 diabetes and glucose intolerance 1, 2
Measure fasting lipid profile including total cholesterol, LDL, HDL, and triglycerides, as insulin resistance drives dyslipidemia with elevated triglycerides, increased small dense LDL, and decreased HDL 1, 2, 5
Calculate BMI and waist-hip ratio to assess central obesity 1, 2
Look for acanthosis nigricans on physical exam, which indicates underlying insulin resistance 1, 3, 5

Initiate multicomponent lifestyle intervention before or concurrent with any pharmacologic therapy, as this is the foundation of the treatment hierarchy 4
Target weight loss of just 5% of initial body weight, which improves metabolic parameters, ovulation rates, and pregnancy outcomes 3
Implement diet, exercise, and behavioral strategies together rather than any single component 4
Emphasize regular exercise and weight control measures before considering drug therapy for dyslipidemia 1, 2

Use metformin as the preferred insulin-sensitizing agent when pharmacologic intervention is warranted, despite lack of FDA approval specifically for PCOS 1, 2, 3, 5
Metformin decreases circulating androgen levels through improved insulin sensitivity 1, 2
Metformin improves or maintains glucose tolerance over time 2
Metformin improves ovulation rates and metabolic outcomes 1, 2, 3, 5
Metformin tends to decrease weight, unlike thiazolidinediones which increase weight 1, 2

When managing women not attempting conception, combination oral contraceptive pills remain first-line for menstrual regulation and androgen suppression, but be aware they may increase triglycerides and HDL cholesterol despite no evidence of increased cardiovascular events compared to the general population 1, 2, 3, 5

Do not overlook acanthosis nigricans, as it may indicate associated insulinoma or malignancy, particularly gastric adenocarcinoma 1
Do not use thiazolidinediones as first-line agents given their tendency to increase weight and variable risk-benefit profiles compared to metformin 1, 2
Do not skip lipid screening—insulin resistance in PCOS creates a particularly atherogenic lipid profile requiring monitoring 1, 2